Cagrilintide

Cagrilintide is a long-acting amylin analog peptide under clinical investigation for metabolic research. It is designed to act on amylin receptors — heteroreceptor complexes of the calcitonin receptor (CALCR) with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) — which are expressed in the area postrema, nucleus tractus solitarius, and hypothalamus.

By activating these receptors, cagrilintide modulates satiety, slows gastric emptying, and suppresses glucagon secretion. It is frequently studied in combination with GLP-1 receptor agonists such as semaglutide, representing a complementary dual-mechanism approach to metabolic regulation research.

• Amylin receptor (CALCR/RAMP complex) pharmacology
• Satiety signaling and gastric emptying modulation studies
• Glucagon suppression and glucose homeostasis research
• Combination protocols with GLP-1 receptor agonists
• Obesity and type 2 diabetes dual-agonist research models
• Pharmacokinetic studies of long-acting amylin analogs

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Amylin analog; often studied alongside semaglutide. Gradual weekly titration.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.